Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

This study has been completed.

Sponsored by:	Novartis
Information provided by:	Novartis
ClinicalTrials.gov Identifier:	NCT00029224

Purpose

Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.

Condition	Intervention	Phase
Breast Cancer Multiple Myeloma Prostate Cancer	Drug: zoledronic acid	Phase IV

Genetics Home Reference related topics: aceruloplasminemia breast cancer hemophilia

MedlinePlus related topics: Breast Cancer Cancer Multiple Myeloma Prostate Cancer

Drug Information available for: Zoledronic acid

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	A Prospective, Multicenter, Open-Label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-Related Bone Lesions

Further study details as provided by Novartis:

Primary Outcome Measures:

Pain score assessed by change from baseline

Secondary Outcome Measures:

Quality of life
Time in infusion chair
Safety assessed by adverse events (AEs)

Estimated Enrollment:	500
Study Start Date:	October 2001

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Signed informed consent
Greater than 18 years of age
Proof of breast cancer, multiple myeloma or prostate cancer
Diagnosis of at least one cancer-related bone lesion
If patient is of child-bearing potential, negative pregnancy test and on a medically recognized form of contraception
ECOG performance status of 0,1 or 2
Ability to read, understand and write English or Spanish language
Normal renal function
Corrected serum calcium equal to or greater than 8mg/dl
No clinically symptomatic brain metastases
No known hypersensitivity to Zometa or other bisphosphonates
Not pregnant or lactating

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00029224

Locations

United States, California
Stockton Hematology Oncology Medical Group
Stockton, California, United States, 95204
United States, Florida
Osceola Cancer Center
Kissimmee, Florida, United States, 34741
United States, Nevada
Nevada Cancer Center
Las Vegas, Nevada, United States, 89109
United States, New Mexico
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, United States, 87102
Hematology-Oncology Associates PC
Albuquerque, New Mexico, United States, 87102
United States, Oregon
Hematology Oncology Associates, PC
Medforo, Oregon, United States, 97504
United States, Virginia
Virginia Physicians, Inc
Richmond, Virginia, United States, 23294

Sponsors and Collaborators

Novartis

More Information

Information about zoledronic acid [Zometa] This link exits the ClinicalTrials.gov site

Study ID Numbers:	CZOL446EUS16
Study First Received:	January 9, 2002
Last Updated:	June 12, 2008
ClinicalTrials.gov Identifier:	NCT00029224
Health Authority:	United States: Food and Drug Administration

Keywords provided by Novartis:

bone lesions
breast cancer
multiple myeloma

prostate cancer
bone metastases
pain

Study placed in the following topic categories:

Genital Neoplasms, Male
Prostatic Diseases
Blood Protein Disorders
Quality of Life
Paraproteinemias
Pain
Urogenital Neoplasms
Hemostatic Disorders
Hemorrhagic Disorders
Multiple myeloma
Neoplasm Metastasis
Breast Diseases
Immunoproliferative Disorders

Zoledronic acid
Skin Diseases
Hematologic Diseases
Blood Coagulation Disorders
Vascular Diseases
Breast Neoplasms
Genital Diseases, Male
Multiple Myeloma
Diphosphonates
Lymphoproliferative Disorders
Prostatic Neoplasms
Neoplasms, Plasma Cell

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Immune System Diseases

Physiological Effects of Drugs
Bone Density Conservation Agents
Cardiovascular Diseases
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009